Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies
Among the 100 or so phytocannabinoids that have been identified in the Cannabis sativa herb, delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been explored the most for pharmacological use. Although 33 states have approved the use of cannabis in the U.S. for medicinal purposes, the U.S. Drug Enforcement Administration recognizes it as a Schedule I drug.
This has impeded the use of cannabis in clinical research, potentially obscuring physicians and nurses about its safety, efficacy, and dosage for pharmaceutical applications through rigorous double-blinded, placebo-controlled studies. Besides, cannabinoid-containing substances obtained for research purposes are not chemically or physically representative of the legal cannabis market.
This has impeded the use of cannabis in clinical research, potentially obscuring physicians and nurses about its safety, efficacy, and dosage for pharmaceutical applications through rigorous double-blinded, placebo-controlled studies. Besides, cannabinoid-containing substances obtained for research purposes are not chemically or physically representative of the legal cannabis market.
GO Prime with only $1.49 now
LATEST
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115